The effect of a plasma next-generation sequencing test on antimicrobial management in immunocompetent and immunocompromised patients—A single-center retrospective study

Abstract

Plasma NGS testing is associated with a change in antimicrobial management in most cases. We observed a decrease in glycopeptide use after NGS results, which highlights physicians' comfort in withdrawing methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) coverage. In addition, antimycobacterial coverage increased, corresponding with early mycobacterial detection by NGS. Further studies are needed to determine effective ways to use NGS testing as an antimicrobial stewardship tool.